MBTG Millennium Biotechnologies Group Inc. featured news, full reports, and detailed charts
Millennium Biotechnologies Group Inc. (MBTG/MBTG.OB) Wrap Up:
Millennium Biotechnologies Group, Inc., through its subsidiary, Millennium Biotechnologies, Inc., operates as a research-based bio-nutraceutical company. The company engages in the research, development, and marketing of nutritional supplements, which comprise RESURGEX, RESURGEX Select, and RESURGEX Plus, which are multi-component nutritional formulas designed to address the multiple nutritional needs (oxidative stress, lean tissue loss, energy depletion, immune support, and weight loss) of immuno-compromised conditions as an adjunct to medical treatment. Its products are used by immuno-compromised individuals undergoing medical treatment for diseases, including cancer, as well as individual...Millennium Biotechnologies Group Inc. (MBTG:OTC Bulletin Board Market)
Snapshot of Millennium Biotechnologies Group Inc. (MBTG)
|
OPEN
$0.0085
|
PREVIOUS CLOSE
$0.0085
|
|
|
DAY HIGH
$0.01
|
DAY LOW
$0.0080
|
|
|
52 WEEK HIGH
01/9/09 - $0.04
|
52 WEEK LOW
08/3/09 - $0.0050
|
|
|
MARKET CAP
4.4M
|
AVERAGE VOLUME 3 mo
539.7K
|
|
|
DILUTED EPS TTM
$-0.02
|
SHARES OUTSTANDING
400.0M
|
|
|
MBTG Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
MBTG Top Compensated Officers
Executives, Board Directors
Key developments for Millennium Biotechnologies Group Inc. (MBTG)
On 11/13/2009, Millennium Biotechnologies Group Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
On September 24, 2009, Millennium Biotechnologies Group Inc. announced that Jerry Swon, Michael Martin and David Sargoy resigned from the Board of Directors on May 5, 2009.
Millennium Biotechnologies Group Inc. announced that Michael C. James has joined Millennium's board of directors as an independent member. Michael James brings a wealth of financial expertise to Millennium's board of directors. He was a board member of Nestor Inc. from 2006 until June 2009, and while acting as CEO, Mr. James turned the company profitable and headed a complete financial restructuring. The business was sold on September 8, 2009 from the Receiver's Estate in Superior Court of the State of Rhode Island.
MBTG Competitors
| Company | Last | Change |
| Abbott Laboratories | $53.64 USD | +0.68 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | MBTG | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 1.7x |
|
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
|
MBTG |
||
MBTG transactions
| Type Date |
Target | |
| No transactions in the last 6 months. | ||